title: Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.
abstract: The BCR-ABL1 fusion gene, the causative lesion of chronic myeloid leukemia (CML) in >95 % of newly presenting patients, offers both a therapeutic and diagnostic target. Reverse-transcription quantitative polymerase chain reaction technology (RT-qPCR), utilizing primer-probe combinations directed to exons flanking the breakpoint junctional region, offers very high levels of both specificity and sensitivity, in a scalable, robust, and cost-effective assay.
authors.affiliation: Imperial Molecular Pathology Laboratory, Imperial College London, G Block 2nd floor, North Corridor, Hammersmith Hospital Campus, Du Cane Road, London, W12 OHS, UK, pierre.foskett@imperial.nhs.uk.
authors.forename: Pierre
authors.initials: P
authors.lastname: Foskett
authors.forename: Gareth
authors.initials: G
authors.lastname: Gerrard
authors.forename: Letizia
authors.initials: L
authors.lastname: Foroni
mesh_terms: D002469:Cell Separation; D003001:Cloning, Molecular; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000235:genetics*; D007962:Leukocytes / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*
chemical_list: D018076:DNA, Complementary; D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl